Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.694 USD -0.86% Intraday chart for Atara Biotherapeutics, Inc. +3.74% +35.34%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Atara Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q4 Revenue $4.3M MT
Atara Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Stocks Edge -2- DJ
North American Morning Briefing : Markets on Hold -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
Atara Says ATA3219 IND Application Approved by FDA for Lupus Nephritis CAR T-Cell Therapy MT
Atara Biotherapeutics Gets FDA Clearance for ATA3219 IND Application DJ
Atara Biotherapeutics Submits New Drug Application to FDA for ATA3219 to Treat Lupus Nephritis MT
Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis CI
Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology CI
Transcript : Atara Biotherapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:45 AM
Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024 CI
Atara Biotherapeutics, Inc. Announces Closing of Expanded Global Tab-Cel Partnership with Pierre Fabre Laboratories CI
Atara Biotherapeutics, Inc.(NasdaqGS:ATRA) dropped from NASDAQ Biotechnology Index CI
Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting CI
Goldman Sachs Cuts Price Target on Atara Biotherapeutics to $0.50 From $3, Maintains Sell Rating MT
North American Morning Briefing : Investors Weigh -2- DJ
Sector Update: Health Care Stocks Falling Late Afternoon MT
Atara Biotherapeutics MT
Top Midday Decliners MT
Evercore ISI Downgrades Atara Biotherapeutics to In Line From Outperform MT
HC Wainwright Downgrades Atara Biotherapeutics to Neutral From Buy MT
Wall Street Set to Open Higher Thursday as Jobless Claims Fall, Ahead of Powell Speech MT
Investors Await Jobless Claims Report, Powell Speech as US Futures Remain Flat in Thursday Trading MT
Chart Atara Biotherapeutics, Inc.
More charts
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The platform leverages the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other serious diseases through the incorporation of engineered chimeric antigen receptors (CARs) or T-cell receptors (TCRs). Its pipeline products include Tab-cel, ATA188, ATA2271, ATA3271, and ATA3219. The Company's T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA188 is used for the treatment of multiple sclerosis.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
0.694 USD
Average target price
4.825 USD
Spread / Average Target
+595.24%
Consensus
  1. Stock
  2. Equities
  3. Stock Atara Biotherapeutics, Inc. - Nasdaq
  4. News Atara Biotherapeutics, Inc.
  5. Atara Biotherapeutics, Bayer Collaboration on CAR T-cell Therapies to be Terminated in September -- Shares Drop in Late Hours